Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 14505
Country/Region: Nigeria
Year: 2016
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $10,205,189 Additional Pipeline Funding: $37,250,124

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $2,982,703
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $2,798,942
Health Systems Strengthening (OHSS) $0
Testing: HIV Testing and Counseling (HVCT) $4,423,544
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 1,382
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 1,174
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 1,634
GEND_GBV_DSD Number of people receiving post-GBV care 2017 2,808
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 97,110
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 86,140
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,212,215
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 539,850
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,935,315
HTC_TST_DSD Service Delivery Point (Community): Index testing 2017 4,863
HTC_TST_DSD Service Delivery Point (Community): Mobile testing 2017 238,286
HTC_TST_DSD Service Delivery Point (Facility): Index testing 2017 2,012
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 2,009
HTC_TST_DSD Service Delivery Point (Facility): Malnutrition facilities 2017 1,035
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 102
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 660,143
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 181,671
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 582,791
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 24,165
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 229,084
HTC_TST_DSD Service Delivery Point (Facility): VMMC 2017 79
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 183,250
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 1,752,065
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 1,935,315
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,494
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,974
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 25,217
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 21,997
OVC_SERV_DSD Age/Sex: 18+ Female 2017 43,623
OVC_SERV_DSD Age/Sex: 18+ Male 2017 43,616
OVC_SERV_DSD By Aggregated Age/Sex: <18 Female 2017 397
OVC_SERV_DSD By Aggregated Age/Sex: <18 Male 2017 396
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 88,032
OVC_SERV_DSD Sum of Age/Sex disaggregates 2017 87,239
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 4,050
PMTCT_ART_DSD New on ART 2017 12,280
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 615,645
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 1,728
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 14,226
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 1,013
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 116
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 15,954
PMTCT_STAT_DSD By: Known positives at entry 2017 24,105
PMTCT_STAT_DSD By: Number of new positives identified 2017 10,641
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 651,040
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 615,645
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 34,746
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 52
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,109
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 47
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,074
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,544
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,282
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 5,952
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 5,358
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 6,620
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 197,304
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 69,763
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 7,416
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 13,230
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 287,713
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 268
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5,515
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 338
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7,044
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 13,165
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 14,725
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 8,170
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 7,472
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 160,578
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 80,994
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 257,214
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 15,642
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 241,572
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 257,214
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 2,209
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 1,955
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 23,647
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 21,177
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 49,008
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 48,988
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 5,565
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 5,584
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 165,159
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 81,380
TX_PVLS_DSD Denominator: Indication: Routine 2017 206,151
TX_PVLS_DSD Denominator: Indication: Targeted 2017 51,537
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 257,688
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 231,566
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 5,009
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 5,021
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 148,417
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 73,119
TX_PVLS_DSD Numerator: Indication: Routine 2017 185,255
TX_PVLS_DSD Numerator: Indication: Targeted 2017 46,311
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,376
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,164
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,373
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,167
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 44,589
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 37,896
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20,777
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17,672
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 57,899
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 68,115
Cross Cutting Budget Categories and Known Amounts Total: $6,903,476
Human Resources for Health $3,338,800
Food and Nutrition: Commodities $250,000
Economic Strengthening $195,000
Renovation $453,594
Gender: Gender Based Violence (GBV) $1,513,627
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $260,485
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Education $39,520
Motor Vehicles: Purchased $852,450